Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(1):15-16; doi:10.1093/jnci/94.1.15
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 1, 15-16, January 2, 2002
© 2002 Oxford University Press

NEWS

Is There Less Resistance on the Chemoresistance Front?

Mike Miller

Since the 1960s, oncologists have known that chemotherapy can cause DNA damage, second cancers, and other serious complications. The increasing popularity of multidrug regimens may increase the possibility of chemoresistance, toxicity, and a myriad of other complications.

At the November 2001 Chemotherapy Foundation meeting in New York, there was much discussion about the efficacy of doublet or triplet therapies for various cancers and the problems that administering these numbers of drugs . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?